Jacobio Pharmaceuticals Group Co., Ltd. (01167.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 5.71

From 52W high−51.01%

Volume948600.00

Market capHKD 4.32B

P/E (TTM)7.3x

P/S (TTM)5.1x

Div yield—

Key dataSep 18, 2026

Open

HKD 5.71

From 52W high

−51.01%

Volume

948600.00

Market cap

HKD 4.32B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.2x

P/E (TTM)

7.3x

RSI (14)

45.5

MomentumView details →

1D Return

−2.45%

YTD Return

−12.56%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

7.3x

EV/EBITDA

4.2x

EV/Sales

3.0x

P/S (TTM)

5.1x

P/B (TTM)

2.7x

ProfitabilityView details →

Gross Margin

94.40%

Net Margin

69.57%

EBITDA Margin

70.51%

ROE (TTM)

37.50%

ROA (TTM)

27.20%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+261.78%

EPS YoY

+1203.57%

FCF YoY

—

Revenue CAGR 3Y

−18.34%

EPS CAGR 3Y

+10.00%

EBITDA YoY

+1013.66%

MomentumView details →

1D Return

−2.45%

YTD Return

−12.56%

1Y Return

−47.40%

RSI (14)

45.5

vs 50D SMA

+2.89%

vs 200D SMA

−9.56%

Capital & dividendView details →

Debt/Equity

0.12x

Current Ratio

8.28x

Quick Ratio

8.28x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.89

EPS Surprise

7612.31%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

7612.31%

Rev Surprise

11.79%

Financials snapshotView financials →

Revenue (TTM)

929.89M

Net Income (TTM)

461.15M

Op. CF (TTM)

—

Next earningsMar 24, 2027 →

Latest newsMore news →

Jacobio Pharma completed the first patient dosing in the Phase IIa clinical trial of its BET inhibitor JAB-8263 for rheumatoid arthritis in China.56d ago

Similar companies

Telix Pharmaceuticals LimitedTLX Veradermics, IncorporatedMANE Ocumension Therapeutics01477.HK Amicus Therapeutics, Inc.FOLD 丰倍生物603334.SH Amylyx Pharmaceuticals, Inc.AMLX Find similar companies →

Latest newsMore news →

Jacobio Pharma completed the first patient dosing in the Phase IIa clinical trial of its BET inhibitor JAB-8263 for rheumatoid arthritis in China.56d ago